Literature DB >> 17634480

Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer.

Miriam Udler1, Ana-Teresa Maia, Arancha Cebrian, Clement Brown, David Greenberg, Mitul Shah, Carlos Caldas, Alison Dunning, Douglas Easton, Bruce Ponder, Paul Pharoah.   

Abstract

PURPOSE: The prognosis of breast cancer varies considerably among individuals, and inherited genetic factors may help explain this variability. Of particular interest are genes involved in defense against reactive oxygen species (ROS) because ROS are thought to cause DNA damage and contribute to the pathogenesis of cancer. PATIENTS AND METHODS: We examined associations between 54 polymorphisms that tag the known common variants (minor allele frequency > 0.05) in 10 genes involved in oxidative damage repair (CAT, SOD1, SOD2, GPX1, GPX4, GSR, TXN, TXN2, TXNRD1, and TXNRD2) and survival in 4,470 women with breast cancer.
RESULTS: Two single nucleotide polymorphisms (SNPs) in GPX4 (rs713041 and rs757229) were associated with all-cause mortality even after adjusting for multiple hypothesis testing (adjusted P = .0041 and P = .0035). These SNPs are correlated with each other (r2 = 0.61). GPX4 rs713041 is located near the selenocysteine insertion sequence element in the GPX4 3' untranslated region, and the rare allele of this SNP is associated with an increased risk of death, with a hazard ratio of 1.27 per rare allele carried (95% CI, 1.13 to 11.43). This effect was not attenuated after adjusting for tumor stage, grade, or estrogen receptor status. We found that the common allele is preferentially expressed in normal lymphocytes, normal breast, and breast tumors compared with the rare allele, but there were no differences in total levels of GPX4 mRNA across genotypes.
CONCLUSION: These data provide strong support for the hypothesis that common variation in GPX4 is associated with prognosis after a diagnosis of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17634480     DOI: 10.1200/JCO.2006.10.0099

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  40 in total

1.  Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.

Authors:  Yafei Li; Zhifu Sun; Julie M Cunningham; Marie C Aubry; Jason A Wampfler; Gary A Croghan; Cassandra Johnson; Danli Wu; Jeremiah A Aakre; Julian Molina; Liewei Wang; V Shane Pankratz; Ping Yang
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer.

Authors:  Miyako Abe; Wanling Xie; Meredith M Regan; Irena B King; Meir J Stampfer; Philip W Kantoff; William K Oh; June M Chan
Journal:  BJU Int       Date:  2011-01       Impact factor: 5.588

3.  Allelic imbalance (AI) identifies novel tissue-specific cis-regulatory variation for human UGT2B15.

Authors:  Chang Sun; Catherine Southard; David B Witonsky; Olufunmilayo I Olopade; Anna Di Rienzo
Journal:  Hum Mutat       Date:  2010-01       Impact factor: 4.878

4.  KLF15 Inhibits Cell Proliferation in Gastric Cancer Cells via Up-Regulating CDKN1A/p21 and CDKN1C/p57 Expression.

Authors:  Chongqi Sun; Pei Ma; Yanfen Wang; Weitao Liu; Qinnan Chen; Yutian Pan; Chenhui Zhao; Yingchen Qian; Jie Liu; Wei Li; Yongqian Shu
Journal:  Dig Dis Sci       Date:  2017-04-18       Impact factor: 3.199

5.  Serum selenium and single-nucleotide polymorphisms in genes for selenoproteins: relationship to markers of oxidative stress in men from Auckland, New Zealand.

Authors:  Nishi Karunasinghe; Dug Yeo Han; Shuotun Zhu; Jie Yu; Katja Lange; He Duan; Roxanne Medhora; Nabitha Singh; James Kan; Waseem Alzaher; Benson Chen; Sarah Ko; Christopher M Triggs; Lynnette R Ferguson
Journal:  Genes Nutr       Date:  2011-12-03       Impact factor: 5.523

6.  There is no relationship between SOD2 Val-16Ala polymorphism and breast cancer risk or survival.

Authors:  Chengdi Wang; Yang Liu; Jian Zhou; Lei Ye; Nan Chen; Min Zhu; Yulin Ji
Journal:  Mol Clin Oncol       Date:  2017-08-14

7.  No evidence of familial correlation in breast cancer metastasis.

Authors:  Alice S Whittemore; Beth Stearman; Vickie Venne; Jerry Halpern; Anna Felberg; Valerie McGuire; Mary Daly; Saundra S Buys
Journal:  Breast Cancer Res Treat       Date:  2009-03-19       Impact factor: 4.872

8.  hPMC2 is required for recruiting an ERbeta coactivator complex to mediate transcriptional upregulation of NQO1 and protection against oxidative DNA damage by tamoxifen.

Authors:  S P Sripathy; L J Chaplin; N W Gaikwad; E G Rogan; M M Montano
Journal:  Oncogene       Date:  2008-07-28       Impact factor: 9.867

9.  Common germ-line polymorphism of C1QA and breast cancer survival.

Authors:  E M Azzato; A J X Lee; A Teschendorff; B A J Ponder; P Pharoah; C Caldas; A T Maia
Journal:  Br J Cancer       Date:  2010-03-23       Impact factor: 7.640

10.  Extent of differential allelic expression of candidate breast cancer genes is similar in blood and breast.

Authors:  Ana-Teresa Maia; Inmaculada Spiteri; Alvin J X Lee; Martin O'Reilly; Linda Jones; Carlos Caldas; Bruce A J Ponder
Journal:  Breast Cancer Res       Date:  2009-12-10       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.